Neurocrine prices Ingrezza

Neurocrine Biosciences Inc. (NASDAQ:NBIX) priced tardive dyskinesia therapy Ingrezza valbenazine at a wholesale acquisition cost (WAC) of $5,275 for a 30-count bottle of 40 mg capsules. At FDA-recommended dosing, the drug's annual cost is more than $127,000.

Neurocrine said it expects FDA approval of an 80 mg formulation of Ingrezza by YE17. It expects a 30-count bottle of the 80 mg formulation "to be priced substantially similar" to the bottle of 40 mg capsules. At a WAC of $5,275, a year's supply of the 80 mg dose would cost about $64,000...